Plume Effect of Fractional Radiofrequency Versus Laser Resurfacing: Considerations in the COVID Pandemic

Rhea-AI Summary

InMode Ltd. (Nasdaq: INMD) announced a peer-reviewed study published in Lasers in Surgery and Medicine exploring the risks associated with plume emissions during skin resurfacing procedures. Conducted by leading medical professionals, the study found that the Erbium: YAG laser emitted over four times more particles than InMode's Morpheus8 fractional RF device, which showed minimal plume emission. The findings support the safety of Morpheus8 technology in elective procedures, according to InMode executives.

Positive

• Demonstrates the safety profile of Morpheus8 device during skin resurfacing.
• Morpheus8 emits significantly fewer harmful particles compared to Erbium: YAG laser.

Negative

• None.

LAKE FOREST, Calif., Nov. 10, 2020 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD), a leading global provider of innovative medical technologies, is pleased to share a groundbreaking peer reviewed study, Plume Effect of Fractional Radiofrequency Versus Laser Resurfacing: Considerations in the COVID Pandemic, published in Lasers in Surgery and Medicine, the official Journal of the American Society for Laser Medicine & Surgery (ASLMS).

This landmark study, conducted by renowned physicians Drs. Erez Dayan, Spero Theodorou, Jay Burns, Bruce Katz, and Jeffrey Dover, investigates the potential risk of exposure to plume, the pathogenic tissue debris and biological matter that is generated during skin resurfacing procedures.

The study objective was to measure the quantity, size, and rate of plume particle emissions produced beyond the ambient environment baseline from two popular technologies, the Erbium: YAG Laser and the Morpheus8 Fractional Radiofrequency device.  Measurements obtained from a commercial-grade particle analyzer indicated a significant difference in the quantity of plume and the particle size produced by each technology. The Erbium: YAG resurfacing laser was found to emit more than four times the particles versus the fractional RF device, which did not emit plume significantly above the ambient baseline.

Dr. Spero Theodorou, InMode Chief Medical Officer and Plastic Surgeon commented, "Ensuring optimal safety during these unprecedented times demands heightened vigilance and a thorough assessment of all technologies used in elective procedures.  The aerosolization of pathogenetic particulate material is a medical consideration that is critical to any product evaluation, and the findings of this clinical paper substantiate the safety profile of Morpheus8's unique multi-level subdermal energy deployment."   

"Morpheus8's disruptive RF technology continues to redefine fractional remodeling by delivering unprecedented functionality and efficacy to physicians and their patients.  This new study categorically affirms InMode as the premier fractional RF solution," said Shakil Lakhani, President of InMode North America.

About InMode 

InMode is a leading global provider of innovative medical technologies.  InMode develops, manufactures, and markets devices harnessing novel radiofrequency ("RF") technology. InMode strives to enable new emerging surgical procedures as well as improve existing treatments. InMode has leveraged its medically-accepted minimally-invasive RF technologies to offer a comprehensive line of products across several categories for plastic surgery, gynecology, dermatology, otolaryngology, and ophthalmology.  For more information about InMode and its wide array of medical technologies, visit www.inmodemd.com.

Press Contact:
Behrman Communications
Amanda Reinstein
areinstein@behrmanpr.com

Investor Contact:
MS-IR LLC
Miri Segal – Scharia
ir@inmodemd.com
Tel: 917-607-8654

View original content:http://www.prnewswire.com/news-releases/plume-effect-of-fractional-radiofrequency-versus-laser-resurfacing-considerations-in-the-covid-pandemic-301169324.html

SOURCE InMode Ltd.

FAQ

What does the new study about InMode (INMD) reveal?

The study finds that InMode's Morpheus8 emits significantly fewer harmful particles compared to the Erbium: YAG laser.

Who conducted the peer-reviewed study on InMode's technology?

The study was conducted by renowned physicians including Drs. Erez Dayan, Spero Theodorou, Jay Burns, Bruce Katz, and Jeffrey Dover.

Where was the study on InMode's Morpheus8 published?

The study was published in the journal Lasers in Surgery and Medicine.

How does InMode's Morpheus8 compare to traditional laser treatments?

Morpheus8 produces less plume, indicating a safer option for patients during procedures.

When was the study regarding InMode's Morpheus8 released?

The study was announced on November 10, 2020.